Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide

Diabetic Medicine

Volumn 33, Issue 3, 2016, Pages 391-394

  Grunberger, George ^a   Forst, T ^b   Fernandez Lando L ^c   Pechtner, V ^d   Shaginian, R ^d   Jia, N ^d   Gough, S ^e  

^a Grunberger Diabetes Institute   (United States)

^b Profil Mainz   (Germany)

^c Lilly Corporate Center   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCOSE BLOOD LEVEL; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ARTICLE; CARBOHYDRATE ANALYSIS; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FASTING BLOOD GLUCOSE; GLUCOSE BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HUMAN; MALE; METABOLISM; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84958767889     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12833     Document Type: Article

References (10)

1. Tanaka M, Ishii H. Improvement in bedtime plasma glucose level serves as a predictor of long-term blood glucose control in patients with Type 2 diabetes: a study with monotherapy of 50/50 premixed insulin analogue three times daily injection. J Diabetes Complicat 2011; 25: 83-89.
2. Karl D, Zhou R, Vlajnic A, Riddle M. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis. Diabet Med 2012; 29: 933-936.
3. Blonde L, Wysham C, Malloy J, Han J. Early Predictors of response to exenatide twice-daily (BID) and once-weekly (QW) therapy. American Diabetes Association - 74th Annual Scientific Sessions, San Francesco CA, 2014. Diabetes 2014; 63: A256.
4. Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 426-433.
5. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149-2158.
6. Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-2167.
7. AstraZeneca. Bydureon US Prescribing Information, 2014.
8. Nathan DM. Glycemic management of type 2 diabetes: how tight is right and how to get there. Arch Intern Med 2008; 168: 2064-2066.
9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
10. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al. American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327-336.